The Big Phar­ma axe: Mer­ck cuts chikun­gun­ya vax, Bris­tol My­ers drops Cy­tomX-part­nered pro­gram, and more

As fourth quar­ter earn­ings come in, Big Phar­mas are dis­clos­ing changes to their pipelines dur­ing their in­vestor calls, and some­times more qui­et­ly in pre­sen­ta­tion ap­pen­dices.

Mer­ck dropped its chikun­gun­ya vac­cine can­di­date, which com­plet­ed a Phase II study. Mer­ck ac­quired the vac­cine through its pur­chase of Themis Bio­science in 2020. In de­vel­op­ing a vac­cine for chikun­gun­ya, a mos­qui­to-borne virus, Val­ne­va is the fron­trun­ner, as it sub­mit­ted its vac­cine to the FDA at the end of De­cem­ber.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER